MRI contrast agent explained

MRI contrast agents are contrast agents used to improve the visibility of internal body structures in magnetic resonance imaging (MRI).[1] The most commonly used compounds for contrast enhancement are gadolinium-based contrast agents (GBCAs). Such MRI contrast agents shorten the relaxation times of nuclei within body tissues following oral or intravenous administration.

Theory of operation

In MRI scanners, sections of the body are exposed to a strong magnetic field causing primarily the hydrogen nuclei ("spins") of water in tissues to be polarized in the direction of the magnetic field. An intense radiofrequency pulse is applied that tips the magnetization generated by the hydrogen nuclei in the direction of the receiver coil where the spin polarization can be detected. Random molecular rotational oscillations matching the resonance frequency of the nuclear spins provide the "relaxation" mechanisms that bring the net magnetization back to its equilibrium position in alignment with the applied magnetic field. The magnitude of the spin polarization detected by the receiver is used to form the MR image but decays with a characteristic time constant known as the T1 relaxation time. Water protons in different tissues have different T1 values, which is one of the main sources of contrast in MR images. A contrast agent usually shortens, but in some instances increases, the value of T1 of nearby water protons thereby altering the contrast in the image.

Most clinically used MRI contrast agents work by shortening the T1 relaxation time of protons inside tissues via interactions with the nearby contrast agent. Thermally driven motion of the strongly paramagnetic metal ions in the contrast agent generate the oscillating magnetic fields that provide the relaxation mechanisms that enhance the rate of decay of the induced polarization. The systematic sampling of this polarization over the spatial region of the tissue being examined forms the basis for construction of the image.

MRI contrast agents may be administered by injection into the blood stream or orally, depending on the subject of interest. Oral administration is well suited to gastrointestinal tract scans, while intravascular administration proves more useful for most other scans.

MRI contrast agents can be classified[2] by their:

Gadolinium(III)

Gadolinium(III) containing MRI contrast agents (often termed simply "gado" or "gad") are the most commonly used for enhancement of vessels in MR angiography or for brain tumor enhancement associated with the degradation of the blood–brain barrier (BBB).[3] [4] Over 450 million doses have been administered worldwide from 1988 to 2017.[5] For large vessels such as the aorta and its branches, the dose can be as low as of body mass. Higher concentrations are often used for finer vasculature.[6] At much higher concentration, there is more T2 shortening effect of gadolinium, causing gadolinium brightness to be less than surrounding body tissues.[7] However at such concentration, it will cause greater toxicity to bodily tissues.[8]

Gd3+ chelates are hydrophilic and do not readily cross the intact blood–brain barrier. Thus, they are useful in enhancing lesions and tumors where the blood–brain barrier is compromised and the Gd(III) leaks out.[9] In the rest of the body, the Gd3+ initially remains in the circulation but then distributes into the interstitial space or is eliminated by the kidneys.

Available gadolinium-based contrast agents (GBCAs) (brand names, approved for human use by EMA[10] and by the FDA in 1988;[11] [12] (standard dose[13] )):

Extracellular fluid agents

Blood pool agents

Hepatobiliary (liver) agents

Safety

See main article: article and Nephrogenic systemic fibrosis. As a free solubilized aqueous ion, gadolinium(III) is highly toxic, but chelated compound are generally regarded as safe enough to be administered. Free Gd3+ has a median lethal dose of (IV, mouse)[17] or but the LD50 is increased by a factor of 31 times[18] when Gd3+ is chelated.[19]

The spectrum of adverse drug reactions is greater with gadolinium-based contrast agents than with iodinated contrast agents (radiocontrast agents).[20]

The use of Gd3+ chelates in persons with acute or chronic kidney disease can cause nephrogenic systemic fibrosis (NSF),[21] [22] [23] a rare but severe systemic disease resembling scleromyxedema and to some extent scleroderma. It may occur months after contrast injection.[24] Patients with deteriorated kidney function are more at risk for NSF, with dialysis patients being more at risk than patients with chronic kidney disease.[25] [26] NSF can be caused by linear and macrocyclic[27] [28] (macrocyclic ionic compounds have been found the least likely to release the Gd3+),[29] [21] gadolinium-containing MRI contrast agents although much more frequently by linear.

Gadolinium has been found to remain in the brain, heart muscle, kidney, liver, and other organs after one or more injections of a linear or macrocyclic gadolinium-based contrast agents, even after a prolonged period of time.[30] [31] The amount differs with the presence of kidney injury at the moment of injection, the molecular geometry of the ligand, and the dose administered.

While NSF is a severe form of disease, gadolinium deposition disease (GDD) is a mild variant with pain (e.g. headache), fatigue, and / or gadolinium depositions.[32]

In vitro studies have found gadolinium-based contrast agents to be neurotoxic,[33] and a study found signal intensity in the dentate nucleus of MRI (indicative of gadolinium deposition) to be correlated with lower verbal fluency.[34] Confusion is often reported as a possible clinical symptom.[33] The FDA has asked doctors to limit the use of gadolinium contrast agents to examinations where necessary information is obtained only through its use.[35] Intrathecal injections of doses higher than 1 mmol are associated with severe neurological complications and can lead to death.[36] [37] The glymphatic system could be the main access of GBCA to the brain in intravenous injection.[38] [39]

Continuing evidence of the retention of gadolinium in brain and other tissues following exposure to gadolinium containing contrast media, has led to a safety review by the Committee for Medicinal Products for Human Use (CHMP) which led the EMA to suspend linear gadolinium-based media, in which Gd3+ has a lower binding affinity, in 2017.[16]

In the United States, the research has led the FDA to revise its class warnings for all gadolinium-based contrast media. It is advised that the use of gadolinium-based media is based on careful consideration of the retention characteristics of the contrast. Extra care being taken in patients requiring multiple lifetime doses, pregnant, and paediatric patients, and patients with inflammatory conditions. Minimizing repeated GBCA imaging studies when possible, particularly closely spaced MRI studies. However, do not avoid or defer necessary GBCA MRI scans.[40]

In December 2017, the FDA announced in a drug safety communication it is requiring these new warnings to be included on all GBCAs. The FDA also called for increased patient education and requiring gadolinium contrast vendors to conduct additional animal and clinical studies to assess the safety of these agents.[41]

The French health authority recommends to use the lowest possible dose of a GBCA and only when essential diagnostic information cannot be obtained without it.[42]

The World Health Organization issued a restriction on use of several gadolinium contrast agents in November 2009 stating that "High-risk gadolinium-containing contrast agents (Optimark, Omniscan, Magnevist, Magnegita, and Gado-MRT ratiopharm) are contraindicated in patients with severe kidney problems, in patients who are scheduled for or have recently received a liver transplant, and in newborn babies up to four weeks of age."[43]

In magnetic resonance imaging in pregnancy, gadolinium contrast agents in the first trimester is associated with a slightly increased risk of a childhood diagnosis of several forms of rheumatism, inflammatory disorders, or infiltrative skin conditions, according to a retrospective study including 397 infants prenatally exposed to gadolinium contrast.[44] In the second and third trimester, gadolinium contrast is associated with a slightly increased risk of stillbirth or neonatal death, by the same study.[44]

Anaphylactoid reactions are rare, occurring in about 0.03–0.1%.

Iron oxide: superparamagnetic

See main article: Superparamagnetic relaxometry. Two types of iron oxide contrast agents exist: superparamagnetic iron oxide (SPIO) and ultrasmall superparamagnetic iron oxide (USPIO). These contrast agents consist of suspended colloids of iron oxide nanoparticles and when injected during imaging reduce the T2 signals of absorbing tissues. SPIO and USPIO contrast agents have been used successfully in some instances for liver lesion evaluation.[45] [46]

Iron platinum: superparamagnetic

Superparamagnetic iron–platinum particles (SIPPs) have been reported and had significantly better T2 relaxivities compared with the more common iron oxide nanoparticles. SIPPs were also encapsulated with phospholipids to create multifunctional SIPP stealth immunomicelles that specifically targeted human prostate cancer cells.[55] These are, however, investigational agents which have not yet been tried in humans. In a recent study, multifunctional SIPP micelles were synthesized and conjugated to a monoclonal antibody against prostate-specific membrane antigen.[55] The complex specifically targeted human prostate cancer cells in vitro, and these results suggest that SIPPs may have a role in the future as tumor-specific contrast agents.

Manganese

Manganese(II) chelates such as Mn-DPDP (mangafodipir) enhance the T1 signal.[56] The chelate dissociates in vivo into manganese and DPDP; the manganese is excreted in bile, while DPDP is eliminated via kidney filtration.[57] Mangafodipir has been used in human neuroimaging clinical trials, including for neurodegenerative diseases such as multiple sclerosis.[58] [59] Manganese(II) ions are often used as a contrast agent in animal studies, often called MEMRI (manganese-enhanced MRI).[60] Because Mn2+ ions can enter cells through calcium transport channels, it has been used for functional brain imaging.[61]

Manganese(III) chelates with porphyrins and phthalocyanines have also been studied.[56]

Unlike the other well-studied iron oxide-based nanoparticles, research on Mn-based nanoparticles is at a relatively early stage.[62]

Oral administration

A wide variety of oral contrast agents can enhance images of the gastrointestinal tract. They include gadolinium and manganese chelates, or iron salts for T1 signal enhancement. SPIO, barium sulfate, air and clay have been used to lower T2 signal. Natural products with high manganese concentration such as blueberry and green tea can also be used for T1 increasing contrast enhancement.[63]

Perflubron, a type of perfluorocarbon, has been used as a gastrointestinal MRI contrast agent for pediatric imaging.[64] This contrast agent works by reducing the number of hydrogen ions in a body cavity, thus causing it to appear dark in the images.

Protein-based MRI contrast agents

See also: Enzyme-activated MR contrast agents. Newer research suggests the possibility of protein based contrast agents, based on the abilities of some amino acids to bind with gadolinium.[65] [66] [67] [68]

See also

External links

Notes and References

  1. Book: Rinck . Peter A. . 2024 . Magnetic resonance contrast agents . Magnetic Resonance in Medicine. A critical introduction. . 14th . TRTF – The Round Table Foundation / EMRF – European Magnetic Resonance Forum . Web site: Magnetic resonance contrast agents . e-Textbook . Magnetic Resonance in Medicine (www.magnetic-resonance.org) .
  2. Geraldes . Carlos F.G.C. . Laurent . Sophie . 2009 . Classification and basic properties of contrast agents for magnetic resonance imaging . Contrast Media & Molecular Imaging . 4 . 1 . 1–23 . 10.1002/cmmi.265 . free . 19156706.
  3. Book: Gyulia . Tircsó . Enricő . Molńar . Tibor . Csupász . Zoltan . Garda . Richárd . Botár . Ferenc K. . Kálmán. Zoltan . Kovács . Ernő . Brücher . Imre . Tóth . 2021 . Chapter 2. Gadolinium(III)-based contrast agents for magnetic resonance imaging: A re-appraisal . Metal Ions in Bio-Imaging Techniques . Springer . 39–70 . 10.1515/9783110685701-008 . 233702931.
  4. Book: Shauanna M. . McLeod . Thomas J. . Mead . 2021 . Chapter 12. Magnetic resonance theranostics: An overview of gadolinium(II)-based strategies and magnetic particle imaging . Metal Ions in Bio-Imaging Techniques. Springer . 347–370 . 10.1515/9783110685701-018 . 233710460.
  5. Balzer, T. . 2017 . Presence of gadolinium (Gd) in the brain and body . Bayer presentation to the September 8, 2017 meeting of the Medical Imaging Drugs Advisory Committee . . Silver Spring, MD . 2022-04-01 . US FDA.
  6. Lentschig . M.G. . Reimer . P. . Rausch-Lentschig . U.L. . Allkemper . T. . Oelerich . M. . Laub . G. . 1998 . Breath-hold gadolinium-enhanced MR angiography of the major vessels at 1.0 T: Dose-response findings and angiographic correlation . 208 . 2 . 353–357 . Radiology . 9680558 . 10.1148/radiology.208.2.9680558.
  7. Lee MJ, Kim MJ, Yoon CS, Song SY, Park K, Kim WS . 2011 . The T2-shortening effect of gadolinium and the optimal conditions for maximizing the CNR for evaluating the biliary system: a phantom study . Korean Journal of Radiology . 12 . 3 . 358–364 . 21603295 . 3088853 . 10.3348/kjr.2011.12.3.358 .
  8. Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK . November 2016 . MRI contrast agents: Classification and application (Review) . International Journal of Molecular Medicine . 38 . 5 . 1319–1326 . 27666161 . 10.3892/ijmm.2016.2744 . free .
  9. Bagnato F, Gauthier SA, Laule C, Moore G, Bove R, Cai Z, Cohen-Adad J, Harrison DM, Klawiter EC, Morrow SA, Öz G, Rooney WD, Smith SA, Calabresi PA, Henry RG, Oh J, Ontaneda D, Pelletier D, Reich DS, Shinohara RT, Sicotte NL . 6 . May 2020 . Imaging mechanisms of disease progression in multiple sclerosis: Beyond brain atrophy . . 30 . 3 . 251–266 . 32418324 . 10.1111/jon.12700. 218677556 .
  10. EMA recommendations on gadolinium-containing contrast agents . . ema.europa.eu . 2018-07-12.
  11. Kanal . Emanuel . Dec 2016 . Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience . Magnetic Resonance Imaging . 34 . 10 . 1341–1345 . 10.1016/j.mri.2016.08.017 . 1873-5894 . 27608608 .
  12. Information on gadolinium-containing contrast agents . Post-market Drug Safety Information for Patients and Providers . 2018-07-12 . fda.gov.
  13. Web site: Gadolinium Based Contrast Dosing Charts .
  14. McDonald . Robert J. . Levine . Deborah . Weinreb . Jeffrey . Kanal . Emanuel . Davenport . Matthew S. . Ellis . James H. . Jacobs . Paula M. . Lenkinski . Robert E. . Maravilla . Kenneth R. . Prince . Martin R. . Rowley . Howard A. . November 2018 . Gadolinium retention: A research roadmap from the 2018 NIH / ACR / RSNA workshop on gadolinium chelates . Radiology . en . 289 . 2 . 517–534 . 10.1148/radiol.2018181151 . 0033-8419 . 6209069 . 30204075.
  15. Web site: Elucirem- gadopiclenol injection . DailyMed . 12 October 2022 . 16 October 2022 . 16 October 2022 . https://web.archive.org/web/20221016202507/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca582f31-1042-487f-82e4-533f1b541902 . live .
  16. EMAs final opinion confirms restrictions on the use of linear gadolinium agents . 17 September 2018 . ema.europa.eu . .
  17. Bousquet . JC . etal . Gd-DOTA: characterization of a new paramagnetic complex . Radiology . March 1988 . 166 . 3 . 693-8 . 10.1148/radiology.166.3.3340763 . 3340763.
  18. Profil toxicologique des chélates de gadolinium pour l'IRM : où en est-on ? . fr . Toxicological profile of gadolinium chelates for MRI: where do we stand? . 2014 . Academie de pharmacie . acadpharm.org .
  19. Penfield . Jeffrey G. . Reilly . Robert F. . 2007 . What nephrologists need to know about gadolinium . Nature Clinical Practice Nephrology . 3 . 12 . 654–668 . 18033225 . 10.1038/ncpneph0660 . 22435496 .
  20. Boehm IB . 2022 . Classification of gadolinium-based contrast agents (GBCAs) – adverse reactions . Magnetic Resonance Imaging . 85 . 1 . 1–2 . 34662698 . 10.1016/j.mri.2021.10.006. 239027228 .
  21. Grobner . T. . 2005 . Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? . Nephrology Dialysis Transplantation . 21 . 4 . 1104–1108 . 10.1093/ndt/gfk062 . free . 16431890.
  22. Marckmann . P. . Skov . L. . Rossen . K. . Dupont . A. . Damholt . M.B. . Heaf . J.G. . Thomsen . H.S. . 2006 . Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging . Journal of the American Society of Nephrology . 17 . 9 . 2359–2362 . 10.1681/ASN.2006060601 . free . 16885403.
  23. Centers for Disease Control and Prevention (CDC) . 2007 . Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents . Morbidity and Mortality Weekly Report (MMWR) . 56 . 7 . 137–141 . 17318112 . Centers for Disease Control and Prevention (CDC) .
  24. Thomsen . H.S. . Morcos . S.K. . Dawson . P. . 2006 . Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? . Clinical Radiology . 61 . 11 . 905–906 . 17018301 . 10.1016/j.crad.2006.09.003.
  25. Kanal . E. . Barkovich . A.J. . Bell . C. . Borgstede . J.P. . Bradley . W.G. . Froelich . J.W. . Gilk . T. . Gimbel . J.R. . Gosbee . J. . Kuhni-Kaminski . Ellisa . Lester . James W. . Nyenhuis . John . Parag . Yoav . Schaefer . Daniel J. . Sebek-Scoumis . Elizabeth A. . Weinreb . Jeffrey . Zaremba . Loren A. . Wilcox . Pamela . Lucey . Leonard . Sass . Nancy . ACR Blue Ribbon Panel on MR Safety . 6 . 2007 . ACR Guidance Document for Safe MR Practices: 2007 . American Journal of Roentgenology . 188 . 6 . 1447–1474 . 17515363 . 10.2214/AJR.06.1616 .
  26. Web site: Gadolinium and NSF: What is fact and what is theory? . 2008 . c2i2.org . volume vi, issue 2 . 2023-07-23.
  27. Lim . Yu Jeong . Bang . Jisun . Ko . Youngsun . Seo . Hyun Min . Jung . Woon Yong . Yi . Joo Hark . Han . Sang Woong . Yu . Mi Yeon . 2020-09-07 . Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: A case report . Journal of Korean Medical Science . 35 . 35 . e293 . 10.3346/jkms.2020.35.e293 . 1598-6357 . 7476800 . 32893521.
  28. Elmholdt . Tina Rask . Jørgensen . Bettina . Ramsing . Mette . Pedersen . Michael . Olesen . Anne Braae . June 2010 . Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol . NDT Plus . 3 . 3 . 285–287 . 10.1093/ndtplus/sfq028 . 1753-0784 . 5477958 . 28657062.
  29. Web site: Questions and Answers . International Society for Magnetic Resonance in Medicine.
  30. Stanescu . A. Luana . Shaw . Dennis W. . Murata . Nozomu . Murata . Kiyoko . Rutledge . Joe C. . Maloney . Ezekiel . Maravilla . Kenneth R. . March 2020 . Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: Pathological confirmation . Pediatric Radiology . 50 . 3 . 388–396 . 10.1007/s00247-019-04535-w . 1432-1998 . 31989188. 210913930.
  31. Bussi . Simona . Coppo . Alessandra . Celeste . Roberto . Fanizzi . Antonello . Fringuello Mingo . Alberto . Ferraris . Andrea . Botteron . Catherine . Kirchin . Miles A. . Tedoldi . Fabio . Maisano . Federico . 6 . 2020-02-04 . dmy-all . Macrocyclic MR contrast agents: Evaluation of multiple-organ gadolinium retention in healthy rats . Insights into Imaging . 11 . 1 . 11 . 10.1186/s13244-019-0824-5 . 1869-4101 . 7000570 . 32020385 . free .
  32. Boehm IB . 2022 . Gadolinium deposition disease (GDD): Does the missing link exist? – A suggested pathologic model . European Journal of Internal Medicine . 105 . 11 . 118–120 . 35864076 . 10.1016/j.ejim.2022.07.008. 250648810 .
  33. Bower . Danielle V. . Richter . Johannes K. . von Tengg-Kobligk . Hendrik . Heverhagen . Johannes T. . Runge . Val M. . August 2019 . Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent . Investigative Radiology . 54 . 8 . 453–463 . 10.1097/RLI.0000000000000567 . 1536-0210 . 31265439 . 164486744 .
  34. Forslin . Y. . Martola . J. . Bergendal . Å. . Fredrikson . S. . Wiberg . M.K. . Granberg . T. . August 2019 . Gadolinium retention in the brain: An MRI relaxometry study of linear and macrocyclic gadolinium-based contrast agents in multiple sclerosis . American Journal of Neuroradiology . 40 . 8 . 1265–1273 . 10.3174/ajnr.A6112 . 0195-6108 . 7048491 . 31248867.
  35. FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI) . FDA Drug Safety Communication . . 18 June 2019 .
  36. Mihilkumar . Patel . Almohannad . Atyani . Jean-Paul . Salameh . Matthew . McInnes . October 2020 . Safety of intrathecal administration of gadolinium-based contrast agents: A systematic review and meta-analysis . Radiology . 297 . 1 . 1527-1315 . 32720867 . 10.1148/radiol.2020191373 . 2021-08-20 . 75–83. 220842011 .
  37. David Anthony . Provenzano . Zachary . Pellis . Leonard . DeRiggi . 2019-04-25 . dmy-all . Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: A case report and a comprehensive evidence-based review . Regional Anesthesia and Pain Medicine . 44 . 7 . 721–729 . 1532-8651 . 31023932 . 10.1136/rapm-2019-100422 . 133608033 . free .
  38. Toshiaki . Taoka . Shinji . Naganawa . 2018-04-10 . Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain . Magnetic Resonance in Medical Sciences . 17 . 2 . 111–119 . 1880-2206 . 29367513 . 5891336 . 10.2463/mrms.rev.2017-0116.
  39. 2019 . Dr. Aashim Bhatia (presenter) . Webinar on the role of the glymphatic system, and the growing awareness with gadolinium (Gd) deposits found in the brain . video . en . live . https://web.archive.org/web/20230126164931/https://i.vimeocdn.com/video/1243428210-b4f1ab9cdf908dec853a906033ea2e5fffa24ad5240aa9ff436143f295c53333-d?mw=2400&mh=1313&q=70 . January 26, 2023.
  40. Web site: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. 2017-12-19. United States Food and Drug Administration.
  41. Web site: FDA warns gadolinium based contrast agents gbcas are retained body; requires new class warnings . 2018-05-16 . . FDA Drug Safety Communication .
  42. Gadolinium pic RI reeval rapport annexe . fr . Gadolinium peak RI re-eval report appendix . has-sante.fr . 2021-08-19.
  43. Pharmaceuticals: Restrictions in use and availability . 2010 . . 14 . who.int.
  44. Mervak . Benjamin M. . Altun . Ersan . McGinty . Katrina A. . Hyslop . W. Brian . Semelka . Richard C. . Burke . Lauren M. . 2019 . MRI in pregnancy: Indications and practical considerations . Journal of Magnetic Resonance Imaging . 49 . 3 . 621–631 . 10.1002/jmri.26317 . 1053-1807 . 30701610 . 73412175.
  45. Nakamura . Hiroshi . Ito . Naoki . Kotake . Fumio . Mizokami . Yuji . Matsuoka . Takeshi . 2000 . Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma . Journal of Gastroenterology . 35 . 11 . 849–855 . 11085494 . 1037632 . 10.1007/s005350070022.
  46. Shahrouki . Puja . Felker . Ely R. . Raman . Steven S. . Jeong . Woo Kyoung . Lu . David S. . Finn . J. Paul . 2021-10-24 . Steady-state ferumoxytol-enhanced MRI: Early observations in benign abdominal organ masses and clinical implications . Abdominal Radiology . 47 . 1 . 460–470 . 10.1007/s00261-021-03271-w . 34689252 . 8776683 . 2366-004X.
  47. Web site: Feridex . Amagpharma.com . 2012-06-20 . dead . https://web.archive.org/web/20120615182847/http://www.amagpharma.com/products/feridex_iv.php . 2012-06-15 .
  48. Web site: Magnetic resonance TIP – MRI database : Resovist . Mr-tip.com . Softways . 2012-06-20.
  49. Web site: Update on Sinerem (TM) in Europe . 2007-12-13 . AMAG Pharmaceuticals . Thefreelibrary.com . 2012-06-20 . 23 March 2019 . https://web.archive.org/web/20190323160818/https://www.thefreelibrary.com/AMAG+Pharmaceuticals%2c+Inc.+Announces+Update+on+Sinerem(TM)+in+Europe.-a0172378541 . dead .
  50. Web site: Newly approved drug therapies (105) GastroMARK (Advanced Magnetics) . CenterWatch . dead . 2012-06-20 . https://web.archive.org/web/20111229114636/http://centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=105 . 2011-12-29 .
  51. Web site: AMAG form 10-K for the fiscal year ended December 31, 2013 . SEC / Edgar .
  52. Web site: NDA 020410 for GastroMark . FDA . 12 February 2017.
  53. 10.3978/j.issn.2223-4292.2011.08.03 . Yi-Xiang J. . Wang . 2011 . Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application . Quantitative Imaging in Medicine and Surgery . 1 . 1 . 35–40 . 3496483 . 23256052 .
  54. Web site: Clariscan solution for injection . 2017-02-22 . dmy-all . Summary of product characteristics . GE Healthcare AS . Oslo, NO . dead . 2017-02-28 . https://web.archive.org/web/20170301092722/http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1487912585095.pdf . 2017-03-01 .
  55. Taylor . Robert M. . Huber . Dale L. . Monson . Todd C. . Ali . Abdul-Mehdi S. . Bisoffi . Marco . Sillerud . Laurel O. . 2011 . Multifunctional iron platinum stealth immunomicelles: Targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging . Journal of Nanoparticle Research . 13 . 10 . 4717–4729 . 22121333 . 3223933 . 2011JNR....13.4717T . 10.1007/s11051-011-0439-3.
  56. Book: Sara . Lacerda. Daouda . Ndiaye. Éva. Tóth . Metal Ions in Bio-Imaging Techniques . Springer . 2021 . 71–99 . Chapter 3. Manganese Complexes as Contrast Agents for Magnetic Resonance Imaging. 10.1515/9783110685701-009 . 233682771.
  57. Harisinghani . Mukesh G. . Jhaveri . Kartik S. . Weissleder . Ralph . Schima . Wolfgang . Saini . Sanjay . Hahn . Peter F. . Mueller . Peter R. . 2001 . MRI contrast agents for evaluating focal hepatic lesions . Clinical Radiology . 56 . 9 . 714–725 . 11585393 . 10.1053/crad.2001.0764.
  58. Sudarshana . D.M. . Nair . G. . Dwyer . J.T. . Steele . S.U. . Suto . D.J. . Wu . T. . Berkowitz . B.A. . Koretsky . A.P . Cortese . I.C.M. . Reich . D.S. . 6 . August 2019 . Manganese-enhanced MRI of the brain in healthy volunteers . American Journal of Neuroradiology . 40 . 8 . 1309–1316 . 10.3174/ajnr.A6152 . free . 31371354 . 6754109.
  59. Suto . D.J. . Nair . G. . Sudarshana . D.M. . Steel . S.U. . Dwyer . J. . Beck . E.S . Ohayon . J. . Koretsky . A.P. . Cortese . I.C.M. . Reich . D.S. . 6 . August 2020 . Manganese-enhanced MRI in patients with multiple sclerosis . American Journal of Neuroradiology . 41 . 9 . 1569–1576 . 10.3174/ajnr.A6665 . free . 32763897 . 7583091 .
  60. Koretsky . Alan P. . Silva . Afonso C. . 2004 . Manganese-enhanced magnetic resonance imaging (MEMRI) . . 17 . 8 . 527–531 . 15617051 . 10.1002/nbm.940 . free .
  61. Lin . Yi-Jen . Koretsky . Alan P. . 1997 . Manganese ion enhances T1-weighted MRI during brain activation: An approach to direct imaging of brain function . Magnetic Resonance in Medicine . 38 . 3 . 378–388 . 9339438 . 10.1002/mrm.1910380305 . 25703430 .
  62. Zhen . Zipeng . Xie . J. . 2012 . Development of Manganese-Based Nanoparticles as Contrast Probes for Magnetic Resonance Imaging . Theranostics . 2 . 1 . 45–54 . 22272218 . 10.7150/thno.3448 . 3263515.
  63. Book: Lee. Joseph K.T. . 2006 . Computed Body Tomography with MRI Correlation . 87 . Lippincott Williams & Wilkins . registration . 978-0-7817-4526-0 . Internet Archive. (Book: equivalent link . 9780781745260 . Google Books . Lee . Joseph K. T. . 23 August 2023 . Lippincott Williams & Wilkins .
  64. Bisset . G.S. . Emery . K.H. . Meza . M.P. . Rollins . N.K. . Don . S. . Shorr . J.S. . 1996 . Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population . Pediatric Radiology . 26 . 6 . 409–415 . 8657479 . 10032242 . 10.1007/BF01387316 .
  65. 10.1002/wnan.1205 . Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers . 2013 . Xue . Shenghui . Qiao . Jingjuan . Pu . Fan . Cameron . Mathew . Yang . Jenny J. . Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology . 163–179 . 23335551 . 5 . 2 . 4011496.
  66. Li . Shunyi . Jiang . Jie . Zou . Jin . Qiao . Jingjuan . Xue . Shenghui . Wei . Lixia . Long . Robert . Wang . Liya . Castiblanco . Adriana . White . Natalie . Ngo . Jen . Mao . Hui . Liu . Zhi-Ren . Yang . Jenny J. . 6 . 2012 . PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities . Journal of Inorganic Biochemistry . 107 . 1 . 111–118 . 22178673 . 3273044 . 10.1016/j.jinorgbio.2011.11.004.
  67. Xue . Shenghui . Qiao . Jingjuan . Hubbard . Kendra . White . Natalie . Wei . Lixia . Li . Shunyi . Liu . Zhi-Reb . Yang . Jenny J. . Yang . J.J. . 6 . 2014 . Design of ProCAs (protein-based Gd3+ MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers . Medicinal Research Reviews . 34 . 5 . 1070–1099 . 24615853 . 10.1002/med.21313 . 42641594 .
  68. Qiao . Jingjuan . Xue . Shenghui . Pu . Fan . White . Natalie . Liu . Zhi-Ren . Yang . Jenny J. . 2014 . Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents . Journal of Biological Inorganic Chemistry . 19 . 2 . 259–270 . 24366655 . 10.1007/s00775-013-1076-3 . 3931309 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MRI contrast agent".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.